$28.66
1.55% today
Nasdaq, Dec 30, 09:46 pm CET
ISIN
US19459J1043
Symbol
COLL

Collegium Pharmaceutical, Inc. Target price 2024 - Analyst rating & recommendation

Collegium Pharmaceutical, Inc. Classifications & Recommendation:

Buy
60%
Hold
40%

Collegium Pharmaceutical, Inc. Price Target

Target Price $42.25
Price $29.11
Potential
Number of Estimates 4
4 Analysts have issued a price target Collegium Pharmaceutical, Inc. 2025 . The average Collegium Pharmaceutical, Inc. target price is $42.25. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 3 Analysts recommend Collegium Pharmaceutical, Inc. to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Collegium Pharmaceutical, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Collegium Pharmaceutical, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 566.77 628.98
22.17% 10.98%
EBITDA Margin 57.29% 63.10%
30.43% 10.14%
Net Margin 7.34% 9.53%
242.69% 29.91%

5 Analysts have issued a sales forecast Collegium Pharmaceutical, Inc. 2024 . The average Collegium Pharmaceutical, Inc. sales estimate is

$629m
Unlock
. This is
4.96% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$632m 5.50%
Unlock
, the lowest is
$627m 4.55%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $567m 22.17%
2024
$629m 10.98%
Unlock
2025
$740m 17.63%
Unlock
2026
$743m 0.37%
Unlock
2027
$694m 6.59%
Unlock
2028
$656m 5.42%
Unlock

5 Analysts have issued an Collegium Pharmaceutical, Inc. EBITDA forecast 2024. The average Collegium Pharmaceutical, Inc. EBITDA estimate is

$397m
Unlock
. This is
9.80% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$402m 11.13%
Unlock
, the lowest is
$392m 8.32%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $325m 59.34%
2024
$397m 22.23%
Unlock
2025
$439m 10.56%
Unlock
2026
$445m 1.32%
Unlock
2027
$386m 13.13%
Unlock
2028
$356m 7.73%
Unlock

EBITDA Margin

2023 57.29% 30.43%
2024
63.10% 10.14%
Unlock
2025
59.32% 5.99%
Unlock
2026
59.88% 0.94%
Unlock
2027
55.69% 7.00%
Unlock
2028
54.33% 2.44%
Unlock

3 Collegium Pharmaceutical, Inc. Analysts have issued a net profit forecast 2024. The average Collegium Pharmaceutical, Inc. net profit estimate is

$60.0m
Unlock
. This is
19.82% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$72.2m 3.44%
Unlock
, the lowest is
$51.6m 31.03%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $41.6m 274.32%
2024
$60.0m 44.19%
Unlock
2025
$83.9m 39.97%
Unlock
2026
$106m 26.56%
Unlock
2027
$127m 19.88%
Unlock

Net Margin

2023 7.34% 242.69%
2024
9.53% 29.91%
Unlock
2025
11.34% 18.99%
Unlock
2026
14.30% 26.10%
Unlock
2027
18.35% 28.32%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ 1.29 1.86
274.32% 44.19%
P/E 15.65
EV/Sales 2.84

3 Analysts have issued a Collegium Pharmaceutical, Inc. forecast for earnings per share. The average Collegium Pharmaceutical, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$1.86
Unlock
. This is
19.83% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$2.24 3.45%
Unlock
, the lowest is
$1.60 31.03%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $1.29 274.32%
2024
$1.86 44.19%
Unlock
2025
$2.60 39.78%
Unlock
2026
$3.30 26.92%
Unlock
2027
$3.95 19.70%
Unlock

P/E ratio

Current 12.56 93.72%
2024
15.65 24.60%
Unlock
2025
11.18 28.56%
Unlock
2026
8.83 21.02%
Unlock
2027
7.37 16.53%
Unlock

Based on analysts' sales estimates for 2024, the Collegium Pharmaceutical, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.98 16.86%
2024
2.84 4.66%
Unlock
2025
2.42 14.99%
Unlock
2026
2.41 0.36%
Unlock
2027
2.58 7.06%
Unlock
2028
2.72 5.73%
Unlock

P/S ratio

Current 1.57 12.61%
2024
1.49 4.72%
Unlock
2025
1.27 14.99%
Unlock
2026
1.26 0.37%
Unlock
2027
1.35 7.06%
Unlock
2028
1.43 5.73%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today